Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics reported positive topline results from the Phase 1 Driving Simulation Trial of GlyphAllo, with the trial meeting its primary endpoint — evening dosing at 375 mg did not impair next-morning driving performance versus placebo on Day 5 after multiple-day dosing. The key secondary endpoint was also met, with a single 250 mg evening dose showing no next-morning driving impairment on Day 2. Zopiclone at 7.5 mg impaired driving as expected, confirming assay sensitivity, and GlyphAllo was well-tolerated with no serious adverse events.
Key figures
- Drug Name
- GlyphAllo (SPT-300 / Glyph Allopregnanolone)
- Phase Of Trial
- Phase 1
- Participants
- 33
- Doses tested mg
- [250,375]
- Positive control
- zopiclone 7.5 mg
- Primary endpoint met
- Yes
- Serious adverse events
- 0
- Key secondary endpoint met
- Yes
- Buoy1 phase2b topline expected
- first half of 2027
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.